EULAR 2023 recommendations for SLE treatment: synopsis for the management of lupus nephritis: the European Renal Association-Immunonephrology Working Group (ERA-IWG) perspective
Nephrol Dial Transplant
.
2024 Apr 26;39(5):727-730.
doi: 10.1093/ndt/gfad230.
Authors
Eleni Frangou
1
,
Annette Bruchfeld
2
3
,
Gema M Fernandez-Juarez
4
,
Jürgen Floege
5
,
Dimitrios Goumenos
6
,
Sarah M Moran
7
,
Stefanie Steiger
8
,
Kate I Stevens
9
,
Kultigin Turkmen
10
,
Andreas Kronbichler
11
Affiliations
1
Department of Nephrology, Limassol General Hospital, Limassol, Cyprus; University of Nicosia Medical School, Nicosia, Cyprus.
2
Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
3
Department of Renal Medicine, Karolinska University Hospital and CLINTEC Karolinska Institutet, Stockholm, Sweden.
4
Department of Nephrology, Hospital Unversitatio La Paz, Madrid, Spain ; Instituto de Investigacion la Paz, IDIPaZ, Spain.
5
Division of Nephrology, RWTH Aachen University Hospital, Aachen, Germany.
6
Department of Nephrology and Renal Transplantation, Patras University Hospital, Patras, Greece.
7
Cork University Hospital, University College Cork, Cork, Ireland.
8
Renal Division, Department of Medicine IV, Ludwig-Maximilians-University Hospital Munich, Ludwig-Maximilians-University Munich, Germany.
9
Glasgow Renal and Transplant Unit, Queen Elizabeth University Hospital, Glasgow, UK.
10
Division of Nephrology, Department of Internal Medicine, Necmettin Erbakan University, Konya, Turkey.
11
Department of Internal Medicine IV, Nephrology and Hypertension, Medical University Innsbruck, Innsbruck, Austria.
PMID:
37881002
DOI:
10.1093/ndt/gfad230
No abstract available
MeSH terms
Disease Management
Europe
Humans
Immunosuppressive Agents / therapeutic use
Lupus Nephritis*
Nephrology* / methods
Nephrology* / standards
Practice Guidelines as Topic
Societies, Medical*
Substances
Immunosuppressive Agents
Grants and funding
CSL Behring
Vifor Pharma
Otsuka Pharmaceutical